Biofrontera AG:Ad hoc: Biofrontera AG decides on capital increase
(Thomson Reuters ONE) -
Biofrontera AG /
/
Ad hoc: Biofrontera AG decides on capital increase
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany, 2 March 2012 - The board of Biofrontera AG has today
decided to increase its base capital from the current EUR 11,740,486.00 by up to
EUR 4,402,682.00 to up to EUR 16,143,168.00 ("Capital Increase") through issuing
up to 4,402,682 new shares against cash payments ("New Shares").
The New Shares are prone to a participation in profits from 1 January 2012. Up
to the ordinary shareholder meeting 2012 and their registration in the regulated
stock market which will occur within the legal deadline, i.e. within one year
from the issuance of the New Shares, they will be booked as "young shares" under
a separate ISIN.
Up to that point in time public trade of the shares in the ISIN DE0006046113
will not be possible. An interim listing in the open market in a separate ISIN
is currently not anticipated by the company. The shareholders are referred to
the risks associated with the limited fungibility of the New Shares.
Shareholders will be offered the legal purchase right in such a way that Lang &
Schwarz Broker GmbH, Düsseldorf, has been selected to take over the shares at
the face value of 1.00 EUR, with the obligation to transfer them to the
shareholders of the company at a ratio of 8 : 3 according to the execution of
purchase rights, at a purchase price of EUR 2.60 per New Share. The subscription
period will begin on 8 March 2012 and last for two weeks. Lang & Schwarz Broker
GmbH will offer the remaining shares to share holders exercising their purchase
rights ("Additional Purchase").
The company and an investor who will be eligible to purchase rights have
furthermore today closed an agreement on the use of purchase rights and the
Additional Purchase of shares from purchase rights that were not exercised. The
agreement is intended to secure the complete placement of the Capital Increase,
under the condition that a minimum purchase of 2,017,896 New Shares will be
assigned to the investor. The safeguarding of the entire placement is void if
the minimal assignment of 2,017,896 New Shares to the investor is not possible
through purchase rights and Additional Purchase. The investor has furthermore
agreed to an obligation to keep the New Shares for at least 24 months from the
registration of the shares in the company's commercial register.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact:
Werner Pehlemann
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail:w.pehlemann(at)biofrontera.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1590938]
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2012 - 12:31 Uhr
Sprache: Deutsch
News-ID 121114
Anzahl Zeichen: 3580
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera AG:Ad hoc: Biofrontera AG decides on capital increase"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
